Effectiveness of Early Favipiravir Therapy in Hospitalised COVID-19 Patients

Table 1

Patients’ raw data.

	Treated with favipiravir (n = 103)	Not treated (n = 62)
Ages, mean (SEM)	58.2 (1.6)	63.3 (2.2)
Survival/death (%)	102/1 (99.1%–0.9%)	45/17 (72.6%–27.4%)
Non-ICU/ICU (%)	82/21 (79.6%–20.4%)	46/16 (74.2%–25.8%)
Comorbidities/no comorbidities (%)	66/37 (64.1%–35.9%)	48/14 (77.4%–22.6%)
Days in hospital (SEM)	9.6 (0.5)	11.4 (1.2)

Difference between the mean age of survival and death rate of COVID-19 patients (n = 165).